A bifunctional anti-PD-L1 antibody/IL-10 fusion protein targeting exhausted T cells for cancer immunotherapy

In this poster at the Society for Immunotherapy of Cancer (SITC) Cytokines in Cancer Immunotherapy Workshop, October 11-12, 2021, the science and some pre-clinical data behind the development of EI-011 using our T-Action platform were presented. We designed a novel, bifunctional anti-PD-L1/IL-10 fusion protein with the goal of delivering IL-10 to PD-L1-high cells in tumors while blocking PD-L1, and evaluated in vitro activity as well as in vivo anti-tumor efficacy. The poster can be seen here.